| Avadel Pharmaceuticals plc | |
| Type: | Public |
| Traded As: | NASDAQ: |
| Location City: | Dublin |
| Location Country: | Ireland |
| Revenue: | $ 150.2M (Dec31, 2016)[1] |
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.[2]
The company was founded as Flamel Technologies SA in Lyon, France in 1990.[3]
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.[4] [5]
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.[6]
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.[7]
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.[8] [9]
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate.[10]